A 27-Year-Old Man with AIDS and Disseminated Histoplasmosis

rgb(204,51,102)
Last updated March 12, 2015
Case Authors: 
Real name: 
Brian R. Wood, MD
Assistant Professor of Medicine
Division of Infectious Diseases
University of Washington School of Medicine
David H. Spach, MD's picture
Real name: 
David H. Spach, MD
Professor of Medicine
Division of Infectious Diseases
Clinical Director, Mountain West AIDS Education and Training Center
University of Washington School of Medicine
Disclosures: 
None
Learning Objectives: 
  1. Summarize the clinical manifestations of HIV-infected persons with disseminated histoplasmosis.
  2. State appropriate therapy for initial managment of progressive disseminated histoplasmosis.

Display Group

References
  1. Wheat J. Endemic mycoses in AIDS: a clinical review. Clin Microbiol Rev. 1995;8:146-59.
  2. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007;20:115-32.
  3. Wheat J. Histoplasmosis in the acquired immunodeficiency syndrome. Curr Top Med Mycol. 1996;7:7-18.
  4. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Endemic mycoses plus aspergillosis: histoplasmosis. May 7, 2013.
  5. McKinsey DS, Spiegel RA, Hutwagner L, et al. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clin Infect Dis. 1997;24:1195-203.
  6. Chaturvedi S, Frame P, Newman SL. Macrophages from human immunodeficiency virus-positive persons are defective in host defense against Histoplasma capsulatum. J Infect Dis. 1995;171:320-7.
  7. Couppié P, Sobesky M, Aznar C, et al. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. Clin Infect Dis. 2003;38:134-8.
  8. Wheat LJ, Chetchotisakd P, Williams B, Connolly P, Shutt K, Hajjeh R. Factors associated with severe manifestations of histoplasmosis in AIDS. Clin Infect Dis. 2000;30:877-81.
  9. Koduri PR, Chundi V, DeMarais P, Mizock BA, Patel AR, Weinstein RA. Reactive hemophagocytic syndrome: a new presentation of disseminated histoplasmosis in patients with AIDS. Clin Infect Dis. 1995;21:1463-5.
  10. Subedee A, Van Sickels N. Hemophagocytic Syndrome in the Setting of AIDS and Disseminated Histoplasmosis: Case Report and a Review of Literature. J Int Assoc Provid AIDS Care. 2015 Feb 10. [Epub ahead of Print]
  11. Joseph Wheat L. Current diagnosis of histoplasmosis. Trends Microbiol. 2003;11:488-94.
  12. Williams B, Fojtasek M, Connolly-Stringfield P, Wheat J. Diagnosis of histoplasmosis by antigen detection during an outbreak in Indianapolis, Ind. Arch Pathol Lab Med. 1994;118:1205-8.
  13. Connolly PA, Durkin MM, Lemonte AM, Hackett EJ, Wheat LJ. Detection of histoplasma antigen by a quantitative enzyme immunoassay. Clin Vaccine Immunol. 2007;14:1587-91.
  14. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807-25.
  15. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137:105-9.
  16. Wheat LJ, Cloud G, Johnson PC, et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother. 2001;45:2354-7.
  17. Wheat LJ, Connolly P, Smedema M, et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother. 2006;57:1235-9.
  18. Restrepo A, Tobón A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect. 2006;54:319-27.
  19. Goldman M, Zackin R, Fichtenbaum CJ, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis. 2004;38:1485-9.
  20. Tobón AM, Agudelo CA, Rosero DS, et al. Disseminated histoplasmosis: a comparative study between patients with acquired immunodeficiency syndrome and non-human immunodeficiency virus-infected individuals. Am J Trop Med Hyg. 2005;73:576-82.
  21. Koo HL, Hamill RJ, Andrade RA. Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. Clin Infect Dis. 2007;45:e77-9.
  22. Crommentuyn KM, Mulder JW, Sparidans RW, Huitema AD, Schellens JH, Beijnen JH. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clin Infect Dis. 2004;38:e73-5.